Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Liuying Township, Taiwan Clinical Trials

A listing of Liuying Township, Taiwan clinical trials actively recruiting patients volunteers.

Found (2183) clinical trials

NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

This is a multicenter, open-label Phase 1b/2a study of NT-I7 in combination with pembrolizumab. The study consists of a dose escalation phase (Phase 1b) followed by a dose expansion phase (Phase 2a). The Phase 1b is designed to assess the safety and tolerability, including determination of the Maximum Tolerated Dose …

Phase

A Phase 1/2 Open-label Multicenter Dose Escalation and Dose Expansion Study of the Safety Tolerability and PK of HPN217 in Patients With R/R MM

An open-label, Phase 1/2 study of HPN217 as monotherapy to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma

Phase

Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age with X-linked Hypophosphatemia (XLH)

Phase

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Objectives Primary objective: To determine the safety and relative efficacy of Chimeric antigen receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer (CB-NK) cells in patients with relapsed/refractory CD19+ B lymphoid malignancies. Secondary Objectives: To assess the overall response rate (complete and partial response rates). To quantify persistence of infused allogeneic donor CAR-transduced …

Phase

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

This is a phase l/II study. The purpose of this study is to test the safety of the study drug neratinib in combination with a standard chemotherapy drug called capecitabine at different doses to find out what effects, if any, it has on people. Capecitabine (Xeloda) is approved by the …

Phase

A Phase 1/2a Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

This is a Phase 1/2a, open-label, multicenter, first-in-human trial to evaluate the safety and tolerability, PK, PD, and preliminary efficacy of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. This trial is divided into three parts: Phase 1 Dose …

Phase

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

Long-term survival in stage IV serous ovarian, peritoneal, and fallopian tube cancer is poor and has not significantly improved over the last decades. Standard treatment consists of debulking surgery and six courses of carboplatin and paclitaxel. Nevertheless, the disease recurs in >90% of women, usually within two years. Since early …

Phase

Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Participants With Advanced or Refractory Solid Tumors

This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 combination in Participants with tumors.

Phase

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02B is to evaluate the safety and efficacy of investigational treatment arms in participants with 1L advanced melanoma …

Phase

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

CAN04 is a first-in-class fully humanized and ADCC enhanced monoclonal antibody, targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP). The CAN04 strategy is to attack the IL1RAP target molecule using an effective antibody-based cancer treatment. In preclinical (in vitro and in vivo) studies, CAN04 has shown two distinct mechanisms of …

Phase